| ORIGINAL ARTICLE |
|
| Year : 2001 | Volume
: 17
| Issue : 2 | Page : 132-140 |
|
|
Prospective double-blind randomized controlled trial of terazosin, finasteride and allylestrenol in the management of benign prostatic hyperplasia
Madhu S Agrawal, Monish Aron
Departments of Urology, S. N. Medical College, Agra, and All India Institute of Medical Sciences, New Delhi, India
Correspondence Address:
Madhu S Agrawal
4/18-C, Bagh Farzana, Civil Lines, Agra- 282002
India
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
Medical management is rapidly becoming a very important part of the armamentarium of the urologist involved in the treatment of benign prostatic hyperplasia. The commonest options for medical management include alpha-blockers, 5-alpha reductase inhibitors, and progestational anti-androgens. We present a double-blind randomized controlled trial evaluating the safety and efficacy of terazosin, finasteride and allylestrenol, the prototype drugs in each of these respective categories. A total of 140 patients who satisfied the inclusion and exclusion criteria were inducted into the trial after an informed consent. They were randomized into 4 groups, which received placebo, terazosin, finasteride and allylestrenol respectively for 6 months. Since 29 patients did not complete 6 months of therapy, there were 111 evaluable patients at the end of the study. We found that these 3 drugs produce comparable improvement in symptom score (-40%), flow rates (-60%) and PVR (-50%) which is significantly better than that in the placebo group. Both allylestrenol and finasteride bring about a comparable reduction in prostate volume (-23%), which is statistically significant as compared to the placebo and terazosin groups. Terazosin in doses of I and 2 mg/ day was, found to be effiective and well-tolerated in the vast majority of our cases. No adverse effects were seen in the placebo and finasteride groups, while 9.6% in the terazosin group had postural hypotension and 10.7% in the allylestrenol group had some loss of libido, problems which were reversible upon cessation of therapy. |
|
|
|
| [FULL TEXT] [PDF Not available]* |
|
 |
|
